Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab

Detalles Bibliográficos
Autores principales: Chikaishi, Yasuhiro, Tanaka, Fumihiro, Honda, Yohei, Inoue, Masaaki, Yoshida, Junichi, Tanaka, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799129/
https://www.ncbi.nlm.nih.gov/pubmed/35117477
http://dx.doi.org/10.21037/tcr.2020.01.24
_version_ 1784641993640509440
author Chikaishi, Yasuhiro
Tanaka, Fumihiro
Honda, Yohei
Inoue, Masaaki
Yoshida, Junichi
Tanaka, Masao
author_facet Chikaishi, Yasuhiro
Tanaka, Fumihiro
Honda, Yohei
Inoue, Masaaki
Yoshida, Junichi
Tanaka, Masao
author_sort Chikaishi, Yasuhiro
collection PubMed
description
format Online
Article
Text
id pubmed-8799129
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87991292022-02-02 Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab Chikaishi, Yasuhiro Tanaka, Fumihiro Honda, Yohei Inoue, Masaaki Yoshida, Junichi Tanaka, Masao Transl Cancer Res Editorial Commentary AME Publishing Company 2020-03 /pmc/articles/PMC8799129/ /pubmed/35117477 http://dx.doi.org/10.21037/tcr.2020.01.24 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Editorial Commentary
Chikaishi, Yasuhiro
Tanaka, Fumihiro
Honda, Yohei
Inoue, Masaaki
Yoshida, Junichi
Tanaka, Masao
Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
title Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
title_full Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
title_fullStr Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
title_full_unstemmed Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
title_short Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
title_sort prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799129/
https://www.ncbi.nlm.nih.gov/pubmed/35117477
http://dx.doi.org/10.21037/tcr.2020.01.24
work_keys_str_mv AT chikaishiyasuhiro prospectsforthefutureofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsincombinationwithbevacizumab
AT tanakafumihiro prospectsforthefutureofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsincombinationwithbevacizumab
AT hondayohei prospectsforthefutureofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsincombinationwithbevacizumab
AT inouemasaaki prospectsforthefutureofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsincombinationwithbevacizumab
AT yoshidajunichi prospectsforthefutureofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsincombinationwithbevacizumab
AT tanakamasao prospectsforthefutureofepidermalgrowthfactorreceptortyrosinekinaseinhibitorsincombinationwithbevacizumab

Ejemplares similares